Author

C. Robles-Planells

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

D. Liu· 2 shared B. G. Allen· 1 shared B. M. Marks· 1 shared B. R. Wels· 1 shared D. Lee· 1 shared D. R. Spitz· 1 shared D. Zepeda-Orozco· 1 shared E. A. Sagastume· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

D. Liu

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pre-clinical Evaluation of Biomarkers for Early Detection of Nephrotoxicity Following Alpha-particle Radioligand Therapy

M. Li, C. Robles-Planells, D. Liu, S. A. Graves, G. Vasquez-Martinez, G. Mayoral-Andrade, D. Lee, P. Rastogi, B. M. Marks, E. A. Sagastume, R. M. Weiss, S. C. Linn-Peirano, F. L. Johnson, M. K. Schultz, D. Zepeda-Orozco

This study evaluates urinary NGAL as a non-invasive biomarker for early detection of tubular damage and long-term nephrotoxicity from alpha-particle radioligand therapy in mice.

bioRxiv · Sep 27, 2023Pharmacology & Toxicology

Auranofin Inhibition of Thioredoxin Reductase Sensitizes Lung Neuroendocrine Tumor Cells (NETs) and Small Cell Lung Cancer (SCLC) Cells to Sorafenib as well as Inhibiting SCLC Xenograft Growth

S. S. Johnson, D. Liu, J. T. Ewald, C. Robles-Planells, K. A. Christiansen, K. Bayanbold, B. R. Wels, S. R. Solst, M. S. ODorisio, B. G. Allen, Y. Menda, D. R. Spitz, M. Fath

This study shows auranofin inhibits TrxR in SCLC and NET cells, sensitizes them to sorafenib, and extends survival in xenograft models without toxicity.

bioRxiv · May 7, 2023Cancer Biology